The Biosimilars Council agrees with the FDA's position that data from a switching study or studies may no longer be necessary to support licensure of interchangeable biosimilar medicines.
BJ's total comparable club sales increased by 3.1% and 2.4% in the second quarter and first six months of fiscal 2024, respectively, compared to the same periods in fiscal 2023.